Acute Myeloid Leukemia: DASATINIB Treatment Study

We are evaluating the effectiveness of DASATINIB for patients with acute myeloid leukemia who did not respond to previous treatments. The study aims to see if this medication can help reduce tumors and identify factors that predict response.

≤3 monthsEfficacy phase (II)No PlaceboStandard MedicinesOralOncology

What diseases are being studied?

Health conditions and diseases that the clinical trial is designed to study and treat.

Who can participate in the clinical trial?

These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..

What medicines are being studied?

Medicines that are officially approved for use in the European Union and considered safe by EMA. These medicines are already on the market and may be tested for new conditions or populations.

Dasatinib Viatris
Dasatinib Viatris is a cancer medicine used to treat certain types of leukemia, such as chronic myeloid leukemia.

What active substances are being studied?

Active substances that are officially approved for use in the European Union and considered safe by EMA. These substances are already on the market and may be tested for new conditions or populations.

Dasatinib
Dasatinib is a substance that treats certain blood cancers by blocking abnormal signals that make cancerous white blood cells grow.

What similar medicines might you know?

Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.

Daruph
Daruph®
Dasa-Abz

Where is the clinical trial being conducted?

Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.

Loading map...
Centre Hospitalier D Avignon
Hématologie clinique et oncologie médicale
Avignon, France
Institut Paoli-Calmettes
Département d'hématologie
Marseille, France
Centre Hospitalier Universitaire De Nice
Département d'hématologie
Nice, France
Sponsor: Institut Paoli-Calmettes
Last updated: Nov 26, 2025

Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.